LIXISENATIDE as an adjunct to insulin therapy in basal type 2 diabetes

A pharmaceutical combination for use in glycemic control in patients with type 2 diabetes, said combination comprising (a) desPro36Exendina-4 (1-39) -Lys6-NH2 or / and a pharmaceutically acceptable salt thereof, (b) a basal insulin or / and a pharmaceutically acceptable salt thereof, and (c) optionally metformin or / and a pharmaceutically acceptable salt thereof, wherein the type 2 diabetes to be treated is not adequately controlled by insulin basal and optionally metformin alone and patient to be treated has a postprandial glucose concentration at 2 hours of at least 14 mmol / l plasma.